Markers for lymphoid neoplasms (CD3, CD5, and CD20), cyclin D1, and BCL2 were negative, and EBER in situ hybridization was also negative, effectively excluding lymphoid and viral-driven differentials. Here, CD5 is linked to lymphoid neoplasm.